Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Harmony Biosciences Holdings (HRMY) EBITDA Margin (2020 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed EBITDA Margin for 6 consecutive years, with 9.22% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin fell 1515.0% to 9.22% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 18.3% through Dec 2025, down 206.0% year-over-year, with the annual reading at 18.3% for FY2025, 206.0% down from the prior year.
  • EBITDA Margin hit 9.22% in Q4 2025 for Harmony Biosciences Holdings, down from 21.29% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 74.91% in Q3 2022 to a low of 11.92% in Q3 2021.
  • Historically, EBITDA Margin has averaged 23.12% across 5 years, with a median of 24.36% in 2024.
  • Biggest five-year swings in EBITDA Margin: soared 8682bps in 2022 and later tumbled -5090bps in 2023.
  • Year by year, EBITDA Margin stood at 24.9% in 2021, then surged by 52bps to 37.83% in 2022, then plummeted by -57bps to 16.11% in 2023, then soared by 51bps to 24.37% in 2024, then crashed by -62bps to 9.22% in 2025.
  • Business Quant data shows EBITDA Margin for HRMY at 9.22% in Q4 2025, 21.29% in Q3 2025, and 19.84% in Q2 2025.